The original LuX-Valve system was associated with 10.3% mortality and 4.0% hospitalization for heart failure at 1 year when ...

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...

The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

The US Centers for Medicare & Medicaid Services (CMS) has finalized its national coverage determination (NCD) for transcatheter tricuspid valve replacement (TTVR) when used to treat patients with ...

Only recently have transcatheter devices arrived on the scene: TriClip is one of two FDA-approved devices for TR, the other being the Evoque tricuspid valve replacement system. The devices may be ...

The funding will be put towards an early feasibility study, designed to determine the clinical effectiveness and safety of Laplace’s transcatheter tricuspid valve replacement system. If ...

CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of symptomatic tricuspid regurgitation. The procedures will be subject to ...

Two-year secondary endpoints were recurrent hospitalizations for heart failure and freedom from death due to any cause or the need for tricuspid valve surgery or another valve-repair procedure.